Literature DB >> 34734325

Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.

Anitha Sriram1, Suma Tangirala1, Srividya Atmakuri1, Sajid Hoque1, Sheela Modani1, Saurabh Srivastava1, Srushti Mahajan1, Indrani Maji1, Rahul Kumar2, Dharmendra Khatri2, Jitender Madan1, Pankaj Kumar Singh3.   

Abstract

The human race is consistently striving for achieving good health and eliminate disease-causing factors. For the last few decades, scientists have been endeavoring to invent and innovate technologies that can substitute the conventional dosage forms and enable targeted and prolonged drug release at a particular site. The novel multi-matrix technology is a type of matrix formulation where the formulation is embraced to have a matrix system with multiple number of matrices. The MMX technology embraces with a combination of outer hydrophilic layer and amphiphilic/lipophilic core layer, within which drug is encapsulated followed by enteric coating for extended/targeted release at the required site. In comparison to conventional oral drug delivery systems and other drug delivery systems, multi-matrix (MMX) technology formulations afford many advantages. Additionally, it attributes for targeting strategy aimed at the colon and offers modified prolonged drug release. Thus, it has emerged rapidly as a potential alternative option in targeted oral drug delivery. However, the development of this MMX technology formulations is a exigent task and also has its own set of limitations. Due to its promising advantages and colon targeting strategy over the other colon targeted drug delivery systems, premier global companies are exploiting its potential. This article review deep insights into the formulation procedures, drug delivery mechanism, advantages, limitations, safety and efficacy studies of various marketed drug formulations of MMX technology including regulatory perspectives and future perspectives.
© 2021. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.

Entities:  

Keywords:  Budesonide; Crohn’s disease; Inflammatory bowel disease; MMX technology; Mesalamine; Multi-matrix tablets; Polymer characterization; Ulcerative colitis

Mesh:

Substances:

Year:  2021        PMID: 34734325     DOI: 10.1208/s12249-021-02133-4

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  124 in total

1.  Recent technological advances in oral drug delivery - a review.

Authors: 
Journal:  Pharm Sci Technolo Today       Date:  2000-04

Review 2.  Unravelling the pathogenesis of inflammatory bowel disease.

Authors:  R J Xavier; D K Podolsky
Journal:  Nature       Date:  2007-07-26       Impact factor: 49.962

Review 3.  Bioresponsive drug delivery systems in intestinal inflammation: State-of-the-art and future perspectives.

Authors:  Niranjan G Kotla; Shubhasmin Rana; Gandhi Sivaraman; Omprakash Sunnapu; Praveen K Vemula; Abhay Pandit; Yury Rochev
Journal:  Adv Drug Deliv Rev       Date:  2018-07-05       Impact factor: 15.470

4.  A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

Authors:  Cosimo Prantera; Angelo Viscido; Livia Biancone; Antonio Francavilla; Lucio Giglio; Massimo Campieri
Journal:  Inflamm Bowel Dis       Date:  2005-05       Impact factor: 5.325

Review 5.  Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment.

Authors:  Catherine Le Berre; Ashwin N Ananthakrishnan; Silvio Danese; Siddharth Singh; Laurent Peyrin-Biroulet
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-10       Impact factor: 11.382

6.  Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: A systematic review.

Authors:  Shahnaz Khan; Ewa Rupniewska; Mackenzie Neighbors; David Singer; Joseph Chiarappa; Camilo Obando
Journal:  J Clin Pharm Ther       Date:  2019-03-14       Impact factor: 2.512

7.  Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort.

Authors:  Kelvin T Thia; William J Sandborn; William S Harmsen; Alan R Zinsmeister; Edward V Loftus
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

Review 8.  New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis.

Authors:  William N Tindall
Journal:  Am J Health Syst Pharm       Date:  2009-03-01       Impact factor: 2.637

Review 9.  Rectal budesonide and mesalamine formulations in active ulcerative proctosigmoiditis: efficacy, tolerance, and treatment approach.

Authors:  George P Christophi; Arvind Rengarajan; Matthew A Ciorba
Journal:  Clin Exp Gastroenterol       Date:  2016-05-19

Review 10.  A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease.

Authors:  Seyed Saeid Seyedian; Forogh Nokhostin; Mehrdad Dargahi Malamir
Journal:  J Med Life       Date:  2019 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.